Skip to main content
Figure 3 | Critical Care

Figure 3

From: Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis

Figure 3

Survival in murine sepsis models and the effects of differing doses of bevacizumab on mortality. A, Kaplan-Meier survival analysis following cecal ligation and puncture (CLP) comparing bevacizumab (Bev)-treated animals administered 0.1 mg/kg (n = 8) or 1.0 mg/kg (n = 8) i.p. 1 h before CLP to controls with CLP (n = 13). The group administered 0.1 mg/kg had a significantly greater survival than the CLP controls (P <0.001). B, Kaplan-Meier survival analysis following lipopolysaccharide (LPS) injection comparing Bev-treated animals administered 0.1 mg/kg (n = 10) or 1.0 mg/kg (n = 10) i.p. 1 h before LPS treatment to mice administered LPS-only (n = 8). Administration of 0.1 mg/kg led to significantly greater survival relative to the LPS-only group (P = 0.028).

Back to article page

Critical Care

ISSN: 1364-8535